Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2189182 | 0.80 | TSHR (0.45) | — | |
| SCHEMBL2189191 | 0.80 | TSHR (0.45) | — | |
| SCHEMBL28833013 | 0.79 | TSHR (0.44) | — | |
| SCHEMBL28475631 | 0.78 | LGALS3 (0.33) | — | |
| SCHEMBL29981924 | 0.78 | TSHR (0.46) | — | |
| SCHEMBL6666772 | 0.77 | PPM1B (0.41) | — | |
| SCHEMBL28214269 | 0.77 | AHCY (0.34) | — | |
| SCHEMBL27609483 | 0.75 | GAA (0.33) | — | |
| SCHEMBL14317077 | 0.75 | AHCY (0.45) | POLB | |
| SCHEMBL27766467 | 0.75 | AHCY (0.45) | POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227617-A1 | Esters Of Glucuronide Prodrugs Of Anthracyclines And Method Of Preparation And Use In Tumor-Selective Chemotherapy | PHARMACHEMIE B.V. (NL) | 2009-09-10 | — | — | US | disclosed |
| EP-2098533-A1 | Esters of glucuronide prodrugs of anthracyclines and method of preparation and use in tumor-selective chemotherapy | PHARMACHEMIE B.V. (NL) | 2009-09-09 | — | — | EP | disclosed |
| EP-2098534-A1 | Esters of glucuronide prodrugs of anthracyclines and method of preparation and use in tumor-selective chemotherapy | PHARMACHEMIE B.V. (NL) | 2009-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227617-A1 | Esters Of Glucuronide Prodrugs Of Anthracyclines And Method Of Preparation And Use In Tumor-Selective Chemotherapy | GALE, UGGT1, UGT1A3 | POLB 2488/4885NPC1 3027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.